Bedaquiline (as part of a longer oral regimen)
Treatment for HIV/AIDS - Multidrug-resistant Tuberculosis without extensive drug resistance
Typical Dosage: 400mg daily for 2 weeks, then 200mg three times a week for 22 weeks
Effectiveness
80%
Safety Score
65%
Clinical Trials
30
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
400mg daily for 2 weeks, then 200mg three times a week for 22 weeks
Time to Effect
2-3 months for significant clinical improvement
Treatment Duration
Bedaquiline component 6-9 months, total regimen 9-18 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$45,000
Monitoring:$4,000
Side Effect Mgmt:$3,000
Total Annual:$52,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$50,000/QALY
QALYs Gained
10
Outcome-Based Costs
Cost per Responder
$65,000
Cost per Remission
$65,000
Comparison vs Older, longer MDR-TB regimens without Bedaquiline
Cost Difference
+$2,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Bedaquiline (as part of a longer oral regimen) Outcomes
for HIV/AIDS - Multidrug-resistant Tuberculosis without extensive drug resistance
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov